LRMR
Larimar Therapeutics Inc
2.90$
-3.4%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures per share in USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.00 | 0.01 | 0.01 | – | 0.03 | 0.09 | 0.08 | 0.10 | 0.03 | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 | |
| 0.00 | -0.01 | -0.01 | – | -0.03 | -0.09 | -0.08 | -0.10 | -0.03 | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | 0.00 | |
| 5.24 | 5.30 | 4.39 | 11.34 | 24.50 | 17.48 | 18.26 | 18.44 | 6.67 | 2.64 | 2.24 | 0.94 | 0.63 | 1.20 | 2.11 | |
| – | – | – | 3.37 | 8.61 | 8.04 | 5.32 | 0.56 | 0.78 | 0.96 | 0.70 | 0.48 | 0.32 | 0.29 | 0.25 | |
| 6.04 | 6.33 | 6.32 | 14.71 | 33.07 | 25.02 | 23.48 | 23.26 | 7.45 | 3.60 | 2.94 | 1.42 | 0.95 | 1.48 | 2.36 | |
| -6.04 | -6.33 | -6.33 | -14.71 | -33.10 | -25.11 | -23.57 | -23.35 | -7.45 | -3.60 | -2.94 | -1.42 | -0.95 | -1.48 | -2.36 | |
| – | 0.04 | – | 0.36 | 0.36 | 0.15 | 0.42 | 0.09 | 0.57 | 0.00 | 0.02 | 0.01 | – | – | – | |
| -6.04 | -6.37 | -6.44 | -15.14 | -33.32 | -25.57 | -23.15 | -23.45 | -7.43 | -3.57 | -2.95 | -1.37 | -0.84 | -1.32 | -2.27 | |
| – | – | – | – | -0.42 | -0.13 | -0.39 | -0.60 | -0.03 | -0.01 | -0.02 | -0.05 | – | – | – | |
| -6.04 | -6.37 | -6.44 | -15.14 | -33.32 | -25.44 | -22.76 | -22.85 | -7.43 | -3.56 | -2.93 | -1.33 | -0.84 | -1.32 | -2.27 | |
| -6.04 | -6.32 | -6.44 | -14.71 | -32.92 | -25.25 | -23.00 | -22.64 | -7.43 | -3.59 | -2.92 | -1.41 | -0.83 | -1.31 | -2.27 |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.